Market Overview:
The global glucuronidase enzymes market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for glucuronidase enzymes from biopharmaceutical companies, hospitals, bioscience research institutions, and others. Additionally, the growing awareness about the benefits of using glucuronidase enzymes is also contributing to the growth of this market.
Product Definition:
?-Glucuronidase Enzymes are enzymes that catalyze the hydrolysis of glucuronic acid derivatives. These enzymes are important in the detoxification and elimination of foreign compounds from the body.
Above 90%:
The global ?-glucuronidase enzymes market size was valued at USD 8.5 million in 2015 and is expected to grow at a CAGR of XX% over the forecast period, to reach USD 11.7 million by 2022.
Above 95%:
The above 95% of the enzyme activity is referred to as the “working” or “effective” level. The level below 95% is termed as the residual enzyme activity and it plays a major role in determining if an animal can digest food or not. Food-grade enzymes are characterized by having less than 5% residual activities, which makes them fit for human consumption.
Application Insights:
The others application segment dominated the global ?-glucuronidase enzymes market in terms of revenue share in 2017. The other applications include personal care & cosmetics, food & beverages and pharmaceuticals. Personal care & cosmetics is expected to be the fastest-growing segment over the forecast period owing to increasing demand for natural skin care products with no side effects.
Food and beverage manufacturers are also making use of this enzyme as it helps in reducing or avoiding formation of nitrosamine, a carcinogenic byproduct when nitrates are converted into Nitrites (a common ingredient used as preservatives). In addition, it plays a vital role in breaking down harmful compounds called heterocycles which form during food processing. These factors are projected to boost product demand across several industries including pharmaceuticals and biopharmaceutical companies over the coming years.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The U.S., being a developed nation, has witnessed an increase in healthcare expenditure over the past few years, which is expected to boost demand for enzymes during the forecast period.
The European region followed North America with a share of more than 20% of total revenue generated globally in 2017.
Growth Factors:
- Increasing demand for glucuronidase enzymes in the pharmaceutical and biotechnology industries for drug discovery and development processes.
- Growing demand from the food and beverage industry for use in detoxification, flavor enhancement, and as processing aids.
- Rising incidence of liver diseases that can be treated with glucuronidase enzymes therapy.
- Increasing application of glucuronidase enzymes in research areas such as proteomics, metabolomics, and glycomics .
Scope Of The Report
Report Attributes
Report Details
Report Title
?-Glucuronidase Enzymes Market Research Report
By Type
Above 90%, Above 95%, Above 99%, Others
By Application
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
By Companies
R&D Systems(US), Novus Biologicals(US), Abcam(UK), Boster Biological Technology(US), Thermo Fisher Scientific(US), Santa Cruz Biotechnology(US), RayBiotech(US), Origene(US), Lifespan Biosciences(US), USBiological(US), Proteintech(US), Genetex(US), Biobyt(UK), Aviva Systems Biology Corporation(US), Fitzgerald Industries International(US), Atlas Antibodies(SE), Abbexa Ltd(UK), Bio-Rad(US), Bioss Antibodies(US), St John's Laboratory Ltd(UK)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global ?-Glucuronidase Enzymes Market Report Segments:
The global ?-Glucuronidase Enzymes market is segmented on the basis of:
Types
Above 90%, Above 95%, Above 99%, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- R&D Systems(US)
- Novus Biologicals(US)
- Abcam(UK)
- Boster Biological Technology(US)
- Thermo Fisher Scientific(US)
- Santa Cruz Biotechnology(US)
- RayBiotech(US)
- Origene(US)
- Lifespan Biosciences(US)
- USBiological(US)
- Proteintech(US)
- Genetex(US)
- Biobyt(UK)
- Aviva Systems Biology Corporation(US)
- Fitzgerald Industries International(US)
- Atlas Antibodies(SE)
- Abbexa Ltd(UK)
- Bio-Rad(US)
- Bioss Antibodies(US)
- St John's Laboratory Ltd(UK)
Highlights of The ?-Glucuronidase Enzymes Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Above 90%
- Above 95%
- Above 99%
- Others
- By Application:
- Biopharmaceutical Companies
- Hospitals
- Bioscience Research Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ?-Glucuronidase Enzymes Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
?-Glucuronidase enzymes are a type of enzyme that helps break down glucuronic acid. Glucuronidase enzymes are found in the liver, pancreas, and intestines. They help to remove toxins from these organs and protect them from damage.
Some of the major players in the ?-glucuronidase enzymes market are R&D Systems(US), Novus Biologicals(US), Abcam(UK), Boster Biological Technology(US), Thermo Fisher Scientific(US), Santa Cruz Biotechnology(US), RayBiotech(US), Origene(US), Lifespan Biosciences(US), USBiological(US), Proteintech(US), Genetex(US), Biobyt(UK), Aviva Systems Biology Corporation(US), Fitzgerald Industries International(US), Atlas Antibodies(SE), Abbexa Ltd(UK), Bio-Rad(US), Bioss Antibodies(US), St John's Laboratory Ltd(UK).
The ?-glucuronidase enzymes market is expected to register a CAGR of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. ?-Glucuronidase Enzymes Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. ?-Glucuronidase Enzymes Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. ?-Glucuronidase Enzymes Market - Supply Chain
4.5. Global ?-Glucuronidase Enzymes Market Forecast
4.5.1. ?-Glucuronidase Enzymes Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. ?-Glucuronidase Enzymes Market Size (000 Units) and Y-o-Y Growth
4.5.3. ?-Glucuronidase Enzymes Market Absolute $ Opportunity
5. Global ?-Glucuronidase Enzymes Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. ?-Glucuronidase Enzymes Market Size and Volume Forecast by Type
5.3.1. Above 90%
5.3.2. Above 95%
5.3.3. Above 99%
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global ?-Glucuronidase Enzymes Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. ?-Glucuronidase Enzymes Market Size and Volume Forecast by Application
6.3.1. Biopharmaceutical Companies
6.3.2. Hospitals
6.3.3. Bioscience Research Institutions
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global ?-Glucuronidase Enzymes Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. ?-Glucuronidase Enzymes Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global ?-Glucuronidase Enzymes Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. ?-Glucuronidase Enzymes Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global ?-Glucuronidase Enzymes Demand Share Forecast, 2019-2026
9. North America ?-Glucuronidase Enzymes Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America ?-Glucuronidase Enzymes Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America ?-Glucuronidase Enzymes Market Size and Volume Forecast by Application
9.4.1. Biopharmaceutical Companies
9.4.2. Hospitals
9.4.3. Bioscience Research Institutions
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America ?-Glucuronidase Enzymes Market Size and Volume Forecast by Type
9.7.1. Above 90%
9.7.2. Above 95%
9.7.3. Above 99%
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America ?-Glucuronidase Enzymes Demand Share Forecast, 2019-2026
10. Latin America ?-Glucuronidase Enzymes Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America ?-Glucuronidase Enzymes Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America ?-Glucuronidase Enzymes Market Size and Volume Forecast by Application
10.4.1. Biopharmaceutical Companies
10.4.2. Hospitals
10.4.3. Bioscience Research Institutions
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America ?-Glucuronidase Enzymes Market Size and Volume Forecast by Type
10.7.1. Above 90%
10.7.2. Above 95%
10.7.3. Above 99%
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America ?-Glucuronidase Enzymes Demand Share Forecast, 2019-2026
11. Europe ?-Glucuronidase Enzymes Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe ?-Glucuronidase Enzymes Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe ?-Glucuronidase Enzymes Market Size and Volume Forecast by Application
11.4.1. Biopharmaceutical Companies
11.4.2. Hospitals
11.4.3. Bioscience Research Institutions
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe ?-Glucuronidase Enzymes Market Size and Volume Forecast by Type
11.7.1. Above 90%
11.7.2. Above 95%
11.7.3. Above 99%
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections y Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe ?-Glucuronidase Enzymes Demand Share, 2019-2026
12. Asia Pacific ?-Glucuronidase Enzymes Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific ?-Glucuronidase Enzymes Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific ?-Glucuronidase Enzymes Market Size and Volume Forecast by Application
12.4.1. Biopharmaceutical Companies
12.4.2. Hospitals
12.4.3. Bioscience Research Institutions
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific ?-Glucuronidase Enzymes Market Size and Volume Forecast by Type
12.7.1. Above 90%
12.7.2. Above 95%
12.7.3. Above 99%
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific ?-Glucuronidase Enzymes Demand Share, 2019-2026
13. Middle East & Africa ?-Glucuronidase Enzymes Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa ?-Glucuronidase Enzymes Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa ?-Glucuronidase Enzymes Market Size and Volume Forecast by Application
13.4.1. Biopharmaceutical Companies
13.4.2. Hospitals
13.4.3. Bioscience Research Institutions
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa ?-Glucuronidase Enzymes Market Size and Volume Forecast by Type
13.7.1. Above 90%
13.7.2. Above 95%
13.7.3. Above 99%
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa ?-Glucuronidase Enzymes Demand Share, 2019-2026
14. Competition Landscape
14.1. Global ?-Glucuronidase Enzymes Market: Market Share Analysis
14.2. ?-Glucuronidase Enzymes Distributors and Customers
14.3. ?-Glucuronidase Enzymes Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. R&D Systems(US)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novus Biologicals(US)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abcam(UK)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Boster Biological Technology(US)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Thermo Fisher Scientific(US)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Santa Cruz Biotechnology(US)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. RayBiotech(US)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Origene(US)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Lifespan Biosciences(US)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. USBiological(US)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Proteintech(US)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Genetex(US)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Biobyt(UK)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Aviva Systems Biology Corporation(US)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Fitzgerald Industries International(US)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Atlas Antibodies(SE)
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Abbexa Ltd(UK)
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Bio-Rad(US)
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Bioss Antibodies(US)
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. St John's Laboratory Ltd(UK)
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
